Chart Analysis
NOX Daily Timeframe Chart as of 26 May 2026
Noxopharm (ASX: NOX) — Sofra™ TLR8-Amplifying Oligonucleotides Achieve Over 200-Fold Immune Activation Boost in Human Skin Biopsies and 3-Fold Increase in Animal Model
On 26 May 2026, Noxopharm Limited (ASX: NOX) announced new preclinical data demonstrating that its proprietary Sofra™ technology platform can significantly amplify Toll-like receptor 8 (TLR8) activity for potential application in immuno-oncology. In ex vivo human skin biopsies, a Sofra TLR8-potentiating oligonucleotide boosted the activity of a clinical-stage small molecule TLR8 agonist (motolimod) by more than 200-fold, as measured by an immune activation biomarker. In an in vivo transgenic mouse model expressing human TLR8, a systemically delivered Sofra oligonucleotide increased TLR8-driven immune response approximately 3-fold compared to the agonist alone, assessed by gene expression of three TLR8-responsive biomarkers in the spleen. The company describes this combinatorial approach — amplifying existing TLR8 agonists rather than replacing them — as a novel mechanism to enhance the cancer-fighting activity of standard-of-care therapies like chemotherapy and radiotherapy. The technology is protected by a granted US patent. Noxopharm is currently scaling up to test the compounds in humanised TLR8 mice and various cancer models in the months ahead.
Key Details at a Glance
| Detail | Value |
|---|---|
| Technology Platform | Sofra™ — proprietary oligonucleotide-based immune modulation |
| Target | Toll-like receptor 8 (TLR8) — innate immune sensor |
| Ex Vivo Result (Human Skin Biopsy) | >200-fold amplification of TLR8-driven immune activation |
| In Vivo Result (Transgenic Mouse) | ~3-fold increase in TLR8-driven immune response (spleen, 3 biomarkers) |
| Agonist Used (Ex Vivo) | Motolimod — clinical-stage TLR8 small molecule agonist |
| Agonist Used (In Vivo) | R848 — TLR7/8 agonist |
| Mechanism | Oligonucleotide amplifies existing TLR8 agonist activity (combinatorial, not standalone) |
| IP Protection | Granted US patent |
| Next Steps | Humanised TLR8 mouse models and cancer models (months ahead) |
| Immuno-Oncology Market (Cited) | US$35 billion (2025) → US$185 billion by 2035 |
| Independent Commentary | Prof. Seija Lehnardt, Charité – Universitätsmedizin Berlin |
| Stage | Preclinical (ex vivo and in vivo; no IND filed for TLR8 program) |
What the Data Shows — Ex Vivo and In Vivo Results
The announcement reports two sets of experimental results:
Ex vivo (human skin biopsies): Human skin biopsies were cultured outside the body. A TLR8-driven immune response was induced using motolimod, a clinical-stage TLR8 agonist. When a Sofra TLR8-potentiating oligonucleotide was added, the level of immune activation increased more than 200-fold compared to the agonist alone, as measured by an immune activation biomarker. The specific biomarker was not disclosed.
In vivo (transgenic mouse model): Transgenic mice expressing human TLR8 were treated with R848 (a TLR7/8 agonist). When combined with a systemically delivered Sofra oligonucleotide, the TLR8-driven immune response in the spleen increased approximately 3-fold, as assessed by gene expression analysis of three TLR8-responsive biomarkers. The specific biomarkers were not named.
The disparity between the >200-fold ex vivo result and the ~3-fold in vivo result is notable. Ex vivo systems involve direct exposure of isolated tissue to the compounds, while in vivo results reflect the complexity of whole-body pharmacokinetics, distribution, metabolism, and immune regulation — typically yielding more modest responses.
What is TLR8 and Why Does It Matter in Oncology
Toll-like receptor 8 (TLR8) is an innate immune sensor that plays a role in detecting pathogen-associated molecular patterns and activating immune responses. TLR8 activation is a recognised area of cancer immunotherapy research, with multiple pharmaceutical companies developing TLR8 agonists — drugs that directly stimulate TLR8 — as potential anti-cancer agents.
Noxopharm's approach is distinct from direct agonism: rather than developing a new TLR8 agonist, the company is developing oligonucleotides (short nucleic acid sequences) that amplify the activity of existing TLR8 agonists. The company describes this as exploiting a novel mechanism uncovered through in-depth studies of TLR8 biology, as published in Nature Immunology and a preprint.
The immuno-oncology market was valued at approximately US$35 billion in 2025 and is projected to reach US$185 billion by 2035 (company-cited forecast).
Noxopharm's Broader Pipeline — Sofra and Chroma Platforms
Noxopharm operates two technology platforms:
Sofra™: The broader platform from which the TLR8 oncology program is derived. Sofra encompasses multiple applications including SOF-SKN (dermatology/autoimmune — HERACLES clinical trials commenced with first human doses in July 2025), SOF-VAC (mRNA vaccine and therapeutics enhancement), and the newly disclosed immuno-oncology application targeting TLR8 amplification for cancer.
Chroma™: Focused on oncology, including CRO-67 (dual-cell therapy drug for pancreatic cancer) and the IONIC program with Veyonda® (combined with Bristol Myers Squibb's Opdivo checkpoint inhibitor for solid tumours). The US FDA approved the IND application for Veyonda in May 2026, enabling the IONIC-1 clinical trial to commence.
The company reported revenue of approximately A$2.82 million (trailing 12 months) and losses of approximately A$4.88 million. Noxopharm raised A$2.5 million in May 2025 for clinical trials and R&D.
Market Context
NOX closed at $0.086 on the announcement day, up +43.3% from a previous close of $0.060, with an intraday high of $0.095. The 52-week range spans $0.043 to $0.135. The stock has been in a sustained decline from its 52-week high of $0.135 (set in H2 2025) to a 52-week low of $0.043 before recovering to the $0.055–$0.065 pre-announcement range. The announcement comes amid strong investor interest in immuno-oncology and TLR-targeting therapies.
Risks & Considerations
Preclinical stage — no human clinical data for TLR8 oncology program: The data reported is from ex vivo (human tissue outside the body) and in vivo (transgenic mouse) experiments. No Investigational New Drug (IND) application has been filed for the TLR8 immuno-oncology program. There is no timeline for clinical trials in cancer patients. The pathway from preclinical data to an approved cancer therapy is typically 7–15 years and has a failure rate exceeding 90%.
Ex vivo ≠ in vivo ≠ clinical: The >200-fold amplification observed in ex vivo human skin biopsies is a controlled, isolated-tissue result. The in vivo result in transgenic mice was a ~3-fold increase — a 67-fold reduction in effect size compared to the ex vivo result. Clinical outcomes in cancer patients may differ further and cannot be predicted from preclinical data.
No cancer model data yet: The announcement describes TLR8 amplification in immune activation assays, not in cancer models. No tumour growth inhibition, survival, or anti-tumour efficacy data has been presented. The company states that testing in cancer models is planned "in the months ahead."
Biomarker identity not disclosed: Neither the immune activation biomarker used in the ex vivo study nor the three TLR8-responsive biomarkers measured in the in vivo study were named. Without knowing what was measured, the clinical relevance of the fold-changes cannot be independently assessed.
Competitive TLR8 landscape: Multiple pharmaceutical companies are developing TLR8 agonists and modulators for cancer, including motolimod (VentiRx/Celgene, which failed in a Phase 2 head and neck cancer trial), and programs from Merck, Novartis, and others. Noxopharm's oligonucleotide-amplifier approach is differentiated but unproven in cancer models.
Pre-revenue biotech with limited cash: Noxopharm reported TTM revenue of A$2.82 million and losses of A$4.88 million. The company raised A$2.5 million in May 2025. The cost of humanised mouse studies, cancer model testing, and eventual IND-enabling studies has not been disclosed. Further funding is likely required.
Multiple programs, limited resources: Noxopharm is simultaneously advancing SOF-SKN (autoimmune/dermatology clinical trials), SOF-VAC (mRNA enhancement), TLR8 oncology (preclinical), CRO-67 (pancreatic cancer), and Veyonda/IONIC-1 (solid tumours). Spreading limited resources across multiple programs increases execution risk.
Key Dates & Timeline
| Date | Event |
|---|---|
| July 2025 | HERACLES autoimmune trial first human doses (SOF-SKN) |
| May 2025 | A$2.5 million capital raise for clinical trials and R&D |
| May 2026 | FDA approves IND for Veyonda (IONIC-1 trial to commence) |
| 6 May 2026 | Noxopharm progresses US regulatory strategy (ASX announcement) |
| 26 May 2026 | TLR8 cancer-fighting data announced; share price moved +43.3% |
| Coming months | Humanised TLR8 mouse cancer model testing planned |
| TBC | IONIC-1 clinical trial commencement (Veyonda + Opdivo) |
| TBC | Further SOF-SKN clinical trial data |
Price Data
- Previous Close: $0.060
- Close Price (26 May 2026): $0.086
- Change (26 May 2026): +43.3%
- 52-Week Range: $0.043 – $0.135
Notable Price Levels
-
$0.135 — 52-week high, set in H2 2025 during a period of positive catalyst flow including the HERACLES autoimmune trial first human doses (July 2025) and SOF-SKN dermatology data presentations. The stock reached $0.135 before entering a sustained decline through Q4 2025 and Q1–Q2 2026, eventually retracing approximately 68% to the $0.043 52-week low. This level represents the maximum valuation the market has previously assigned to the Sofra/Chroma dual-platform narrative and sits approximately 57% above the announcement-day close — a significant distance indicating the stock has recovered less than half of its peak-to-trough decline despite the TLR8 data.
-
$0.099 — a prior trading level from the stock's post-peak decline in late 2025, where NOX consolidated during its descent from $0.135. This zone represents the last area of meaningful trading activity in the upper half of the 52-week range and would be the first zone of substantial overhead supply from holders who accumulated during the 2025 rally and may look to exit near their entry. A move above $0.099 would place the stock back above the $0.10 psychological threshold.
-
$0.097 — a historical consolidation zone from the late 2025 sell-off period, closely aligned with the $0.099 zone. Together, the $0.097–$0.099 range forms a cluster of overhead supply that the stock would need to absorb on any continuation.
-
$0.095 — intraday high on announcement day (26 May 2026). The stock traded to this level (+58% intraday) before fading to close at $0.086 — a 9.5% pullback from the session high. The rejection from $0.095 indicates selling pressure emerged just below the $0.097–$0.099 overhead supply cluster, suggesting the stock encountered resistance from the prior trading range before reaching the higher consolidation zone. The close at $0.086 positions the stock in the lower half of its intraday range.
-
$0.092 — an intermediate level between the intraday high ($0.095) and the close ($0.086). This zone saw two-way trading activity during the session and represents the area where buying momentum began to fade.
-
$0.086 — announcement-day close. The +43.3% gap-up from $0.060 establishes this as the new reference level. However, the close in the lower portion of the session's range ($0.060 open area → $0.095 high → $0.086 close) indicates sellers gained the upper hand during the session — a less constructive close pattern than stocks that hold near session highs.
-
$0.075 — the approximate midpoint of the announcement-day gap ($0.060 to $0.086, midpoint ~$0.073). This gap zone has no prior volume history — the stock moved through it on the gap-up with no consolidation. In a retracement, this is a gap-fill zone with no natural support from previous buyers. The $0.075 level also aligns approximately with a brief consolidation point from the stock's late 2025 decline.
-
$0.060 — previous close immediately prior to the announcement and the bottom of the gap-up window. The stock had been consolidating around $0.055–$0.065 in the weeks leading up to the TLR8 announcement, following its recovery from the $0.043 52-week low. A full retracement to $0.060 would represent a complete unwinding of the TLR8 data premium.
-
$0.043 — 52-week low, set during the deepest point of the stock's decline from the $0.135 peak. At this price, NOX's market capitalisation was approximately A$13 million. A return to this level would represent a complete reversal of both the TLR8 announcement premium and the Q2 2026 recovery from the 52-week low, pricing the company back to its most pessimistic valuation of the past 12 months.
Key Takeaways
- NOX moved +43.3% on 26 May 2026 following a price-sensitive ASX disclosure, with an intraday high of $0.095.
- The announcement — New data confirms cancer-fighting potential — was the primary catalyst for the price movement.
- Noxopharm's Sofra™ TLR8-potentiating oligonucleotides achieved more than 200-fold amplification of TLR8-driven immune activation in ex vivo human skin biopsies and approximately 3-fold in an in vivo transgenic mouse model — demonstrating a novel combinatorial approach to immuno-oncology.
- The technology is protected by a granted US patent and is positioned as an amplifier of existing TLR8 agonists (not a standalone therapy), with potential to enhance standard-of-care chemotherapy and radiotherapy.
- The data is preclinical only — no cancer model efficacy data has been generated, no IND has been filed for the TLR8 oncology program, and no clinical trial timeline has been disclosed. Testing in humanised TLR8 mouse cancer models is planned for the coming months.
- Noxopharm is simultaneously advancing multiple programs (SOF-SKN autoimmune, SOF-VAC mRNA, TLR8 oncology, CRO-67, Veyonda/IONIC-1) with limited cash resources. The company reported TTM losses of A$4.88 million.
Summary
Noxopharm announced new preclinical data showing its Sofra™ TLR8-potentiating oligonucleotides achieved more than 200-fold amplification of immune activation in ex vivo human skin biopsies and approximately 3-fold in an in vivo transgenic mouse model when combined with existing TLR8 agonists. The announcement coincided with a +43.3% move to $0.086. The technology represents a combinatorial approach to immuno-oncology — amplifying existing TLR8 drugs rather than replacing them — protected by a granted US patent. The immuno-oncology market is projected to grow from US$35 billion (2025) to US$185 billion by 2035. However, the data is preclinical only, with no cancer model efficacy results, no IND filed for the TLR8 oncology program, and no clinical trial timeline. The company is scaling up to test the compounds in humanised TLR8 mouse cancer models in the months ahead. Noxopharm reported TTM losses of A$4.88 million and is simultaneously advancing multiple programs across the Sofra and Chroma platforms with limited cash resources.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.